VOLUME 2, ISSUE 1, P9-15, MARCH 01, 2021
Teru Jellerette-Nolan, Ph.D., Amber R. Cooper, M.D., Kevin J. Doody, M.D., John E. Nichols, M.D., John K. Park, M.D., Robin L. Poe-Zeigler, M.D., Andrew F. Khair, Ph.D., Laura M. Stong, Ph.D., Richard J. Paulson, M.D., Gaurang S. Daftary, M.D.
To describe the current practice indications, methodology, and outcomes from a real-world experience of intravaginal culture (IVC) using INVOCELL.
A descriptive study outlining real-world experience with INVOCELL that addresses patient selection, ovarian stimulation, embryology laboratory practices, and outcomes.
Five fertility centers in Missouri, Texas, North Carolina, South Carolina, and Virginia.
Four hundred sixty-three patients undergoing 526 cycles.
IVC using INVOCELL.
Main Outcome Measures
Cumulative pregnancy rate and live births. Secondary outcomes of interest included percent good quality embryos.
IVC with INVOCELL was primarily used in women <38 years with anti-Mullerian hormone level >0.8 ng/mL. The mean numbers of retrieved oocytes ranged from 9.2 to 16. Mean numbers of oocytes and sperm-injected oocytes loaded per INVOCELL ranged from a mean of 6.4–9.5 with a reported maximum of 34 oocytes loaded into the device. Most (95%) of the embryos were transferred on day 5. The mean blastocyst recovery per oocyte loaded into the device ranged from 19% to 34%; mean cumulative live birth plus ongoing pregnancy rates ranged from 29% to 53% per cycle start and 40% to 61% per transfer.
This study of IVC using INVOCELL as an alternative model for infertility treatment confirms its utility as a viable alternative to standard incubator-based in vitro fertilization. The technology is compatible within the current framework of practice patterns and, when appropriately used, results in acceptable blastocyst recovery and live birth rates. Further use of INVOCELL in other clinical situations is warranted.